Investors

CANTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:

• The Jefferies Global Healthcare Conference on Thursday, June 7^th at 9:30 a.m. ET in New York City
  
  
• The William Blair Growth Stock Conference on Wednesday, June 13^th at 7:00 a.m. ET in Chicago

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain. 

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:
Alex Dasalla
adasalla@collegiumpharma.com

Source: Collegium Pharmaceutical, Inc.